{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:28:10Z","timestamp":1789140490125,"version":"build-2803163510"},"reference-count":78,"publisher":"Bentham Science Publishers Ltd.","issue":"30","funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021A1515010197"],"award-info":[{"award-number":["2021A1515010197"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhongshan Municipal Natural Science Foundation","award":["200805173640573"],"award-info":[{"award-number":["200805173640573"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Neuropathic pain (NP) is a complex symptom related to nerve damage. The discovery of new drugs for treating chronic NP has been continuing for several decades, while more progress is still needed because of the unsatisfactory efficacy and the side effects of the currently available drugs. Among all the approved drugs for chronic NP, voltage- gated calcium channel (VGCC) \u03b12\u03b4 subunit ligands, also known as gabapentinoids, are among the first-line treatment and represent a class of efficacious and relatively safe therapeutic agents. However, new strategies are still needed to be explored due to the unsatisfied response rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>The aim of the study is to review the latest status of the discovery and development of gabapentinoids for the treatment of chronic NP by covering both the marketed and the preclinical\/clinical ones. Moreover, it aims to analyze the structure-activity relationship (SAR) of gabapentinoids to facilitate the future design of structurally novel therapeutic agents targeting the VGCC \u03b12\u03b4 subunit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We searched PubMed Central, Embase, Cochrane Library, Web of Science, Scopus, and Espacenet for the literature and patents on diabetic peripheral neuropathic pain, postherpetic neuralgia, fibromyalgia, voltage-gated calcium channel \u03b12\u03b4 subunit and related therapeutic agents from incipient to June 10, 2021. The SAR of gabapentinoids was analyzed by pharmacophore modeling using the Phase module in the Schr\u00f6dinger suite.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A variety of gabapentinoids were identified as VGCC \u03b12\u03b4 ligands that have ever been under development to treat chronic NP. Among them, four gabapentinoids are marketed, one is in the active late clinical trials, and eight have been discontinued. Pharmacophore models were generated using the phase module in the Schr\u00f6dinger suite, and common pharmacophores were predicted based on pharmacophoric features and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The latest progress in the discovery and development of gabapentinoids for the treatment of chronic NP was reviewed. Moreover, the structure-activity relationship (SAR) of gabapentinoids has been analyzed by pharmacophore modeling, which will be valuable for the future design of structurally novel therapeutic agents targeting the VGCC \u03b12\u03b4 subunit.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867329666220407093727","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T06:06:14Z","timestamp":1649484374000},"page":"5097-5112","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Review of Voltage-gated Calcium Channel \u03b12\u03b4 Subunit Ligands for the Treatment of Chronic Neuropathic Pain and Insight into Structure-activity Relationship (SAR) by Pharmacophore Modeling"],"prefix":"10.2174","volume":"29","author":[{"given":"Yuting","family":"Chen","sequence":"first","affiliation":[{"name":"Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsheng","family":"Jin","sequence":"additional","affiliation":[{"name":"Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlan","family":"Qin","sequence":"additional","affiliation":[{"name":"Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-0618","authenticated-orcid":true,"given":"Fancui","family":"Meng","sequence":"additional","affiliation":[{"name":"Tianjin Institute of Pharmaceutical Research, Tianjin 300301, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-2909","authenticated-orcid":true,"given":"Guilong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China"},{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.mayocp.2015.01.018","volume":"90","author":"Gilron I.","year":"2015","unstructured":"Gilron I.; Baron R.; Jensen T.; Neuropathic pain: Principles of diagnosis and treatment. Mayo Clin Proc 2015,90(4),532-545","journal-title":"Mayo Clin Proc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11892-014-0538-5","volume":"14","author":"Lauria G.","year":"2014","unstructured":"Lauria G.; Ziegler D.; Malik R.; Merkies I.S.; Waxman S.G.; Faber C.G.; Group P.S.; The role of sodium channels in painful diabetic and idiopathic neuropathy. Curr Diab Rep 2014,14(10),538","journal-title":"Curr Diab Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.18773\/austprescr.2018.022","volume":"41","author":"Murnion B.P.","year":"2018","unstructured":"Murnion B.P.; Neuropathic pain: Current definition and review of drug treatment. Aust Prescr 2018,41(3),60-63","journal-title":"Aust Prescr"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"7408508","DOI":"10.1155\/2020\/7408508","volume":"2020","author":"Cherif F.","year":"2020","unstructured":"Cherif F.; Zouari H.G.; Cherif W.; Hadded M.; Cheour M.; Damak R.; Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Res Manag 2020,2020,7408508","journal-title":"Pain Res Manag"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"Deeks E.D.","year":"2019","unstructured":"Deeks E.D.; Mirogabalin: First global approval. Drugs 2019,79(4),463-468","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/JPR.S45966","volume":"6","author":"Snedecor S.J.","year":"2013","unstructured":"Snedecor S.J.; Sudharshan L.; Cappelleri J.C.; Sadosky A.; Desai P.; Jalundhwala Y.J.; Botteman M.; Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. J Pain Res 2013,6,539-547","journal-title":"J Pain Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1021\/jm061015w","volume":"50","author":"Butera J.A.","year":"2007","unstructured":"Butera J.A.; Current and emerging targets to treat neuropathic pain. J Med Chem 2007,50(11),2543-2546","journal-title":"J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/JPR.S127014","volume":"10","author":"DiBonaventura M.D.","year":"2017","unstructured":"DiBonaventura M.D.; Sadosky A.; Concialdi K.; Hopps M.; Kudel I.; Parsons B.; Cappelleri J.C.; Hlavacek P.; Alexander A.H.; Stacey B.R.; Markman J.D.; Farrar J.T.; The prevalence of probable neuropathic pain in the US: Results from a multimodal general-population health survey. J Pain Res 2017,10,2525-2538","journal-title":"J Pain Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1526-4637.2009.00588.x","volume":"10","author":"Yawn B.P.","year":"2009","unstructured":"Yawn B.P.; Wollan P.C.; Weingarten T.N.; Watson J.C.; Hooten W.M.; Melton L.J.; The prevalence of neuropathic pain: Clinical evaluation compared with screening tools in a community population. Pain Med 2009,10(3),586-593","journal-title":"Pain Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/j.pain.0000000000001744","volume":"161","author":"Gylfadottir S.S.","year":"2020","unstructured":"Gylfadottir S.S.; Christensen D.H.; Nicolaisen S.K.; Andersen H.; Callaghan B.C.; Itani M.; Khan K.S.; Kristensen A.G.; Nielsen J.S.; Sindrup S.H.; Andersen N.T.; Jensen T.S.; Thomsen R.W.; Finnerup N.B.; Diabetic polyneuropathy and pain, prevalence, and patient characteristics: A cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain 2020,161(3),574-583","journal-title":"Pain"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/CEOR.S203920","volume":"11","author":"Yu S.Y.","year":"2019","unstructured":"Yu S.Y.; Fan B.F.; Yang F.; DiBonaventura M.; Chen Y.X.; Li R.Y.; King-Concialdi K.; Kudel I.; Hlavacek P.; Hopps M.; Udall M.; Sadosky A.; Cappelleri J.C.; Patient and economic burdens of postherpetic neuralgia in China. Clinicoecon Outcomes Res 2019,11,539-550","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40122-019-0127-z","volume":"8","author":"Yang F.","year":"2019","unstructured":"Yang F.; Yu S.; Fan B.; Liu Y.; Chen Y.X.; Kudel I.; Concialdi K.; DiBonaventura M.; Hopps M.; Hlavacek P.; Cappelleri J.C.; Sadosky A.; Parsons B.; Udall M.; The epidemiology of herpes zoster and postherpetic neuralgia in China: Results from a cross-sectional study. Pain Ther 2019,8(2),249-259","journal-title":"Pain Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/13543784.2016.1197906","volume":"25","author":"Lawson K.","year":"2016","unstructured":"Lawson K.; Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs 2016,25(9),1071-1081","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DMSO.S37415","volume":"6","author":"Sadosky A.","year":"2013","unstructured":"Sadosky A.; Schaefer C.; Mann R.; Bergstrom F.; Baik R.; Parsons B.; Nalamachu S.; Nieshoff E.; Stacey B.R.; Anschel A.; Tuchman M.; Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013,6,79-92","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1111\/pme.12502","volume":"15","author":"Schaefer C.","year":"2014","unstructured":"Schaefer C.; Mann R.; Sadosky A.; Daniel S.; Parsons B.; Nieshoff E.; Tuchman M.; Nalamachu S.; Anschel A.; Stacey B.R.; Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: A patient-centered evaluation. Pain Med 2014,15(12),2105-2119","journal-title":"Pain Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4149\/gpb_2014037","volume":"34","author":"Geisler S.","year":"2015","unstructured":"Geisler S.; Sch\u00f6pf C.L.; Obermair G.J.; Emerging evidence for specific neuronal functions of auxiliary calcium channel \u03b1\u03b4 subunits. Gen Physiol Biophys 2015,34(2),105-118","journal-title":"Gen Physiol Biophys"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1113\/JP272262","volume":"594","author":"Dolphin A.C.","year":"2016","unstructured":"Dolphin A.C.; Voltage-gated calcium channels and their auxiliary subunits: Physiology and pathophysiology and pharmacology. J Physiol 2016,594(19),5369-5390","journal-title":"J Physiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12013-016-0757-2","volume":"74","author":"Xiang B.","year":"2016","unstructured":"Xiang B.; Liu Y.; Xie L.; Zhao Q.; Zhang L.; Gan X.; Yu H.; The osteoclasts attach to the bone surface where the extracellular calcium concentration decreases. Cell Biochem Biophys 2016,74(4),553-558","journal-title":"Cell Biochem Biophys"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.conb.2020.04.007","volume":"63","author":"Risher W.C.","year":"2020","unstructured":"Risher W.C.; Eroglu C.; Emerging roles for \u03b12\u03b4 subunits in calcium channel function and synaptic connectivity. Curr Opin Neurobiol 2020,63,162-169","journal-title":"Curr Opin Neurobiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2007.03.005","volume":"28","author":"Davies A.","year":"2007","unstructured":"Davies A.; Hendrich J.; Van Minh A.T.; Wratten J.; Douglas L.; Dolphin A.C.; Functional biology of the \u03b1(2)\u03b4 subunits of voltage-gated calcium channels. Trends Pharmacol Sci 2007,28(5),220-228","journal-title":"Trends Pharmacol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1172\/JCI43195","volume":"120","author":"Burgess G.","year":"2010","unstructured":"Burgess G.; Williams D.; The discovery and development of analgesics: New mechanisms, new modalities. J Clin Invest 2010,120(11),3753-3759","journal-title":"J Clin Invest"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.conb.2010.05.007","volume":"20","author":"Bauer C.S.","year":"2010","unstructured":"Bauer C.S.; Tran-Van-Minh A.; Kadurin I.; Dolphin A.C.; A new look at calcium channel \u03b12\u03b4 subunits. Curr Opin Neurobiol 2010,20(5),563-571","journal-title":"Curr Opin Neurobiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"16412","DOI":"10.1523\/JNEUROSCI.1026-13.2013","volume":"33","author":"Patel R.","year":"2013","unstructured":"Patel R.; Bauer C.S.; Nieto-Rostro M.; Margas W.; Ferron L.; Chaggar K.; Crews K.; Ramirez J.D.; Bennett D.L.; Schwartz A.; Dickenson A.H.; Dolphin A.C.; \u03b12\u03b4-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage. J Neurosci 2013,33(42),16412-16426","journal-title":"J Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"Zamponi G.W.","year":"2015","unstructured":"Zamponi G.W.; Striessnig J.; Koschak A.; Dolphin A.C.; The Physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 2015,67(4),821-870","journal-title":"Pharmacol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"H117","DOI":"10.1152\/ajpheart.00122.2009","volume":"297","author":"Fuller-Bicer G.A.","year":"2009","unstructured":"Fuller-Bicer G.A.; Varadi G.; Koch S.E.; Ishii M.; Bodi I.; Kadeer N.; Muth J.N.; Mikala G.; Petrashevskaya N.N.; Jordan M.A.; Zhang S.P.; Qin N.; Flores C.M.; Isaacsohn I.; Varadi M.; Mori Y.; Jones W.K.; Schwartz A.; Targeted disruption of the voltage-dependent calcium channel \u03b12\/\u03b4-1-subunit. Am J Physiol Heart Circ Physiol 2009,297(1),H117-H124","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2398212818794805","volume":"2","author":"Dolphin A.C.","year":"2018","unstructured":"Dolphin A.C.; Voltage-gated calcium channels: Their discovery, function and importance as drug targets. Brain Neurosci Adv 2018,2,1-8","journal-title":"Brain Neurosci Adv"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2174\/0929867326666190530121133","volume":"27","author":"Caroleo M.C.","year":"2020","unstructured":"Caroleo M.C.; Brizzi A.; De Rosa M.; Pandey A.; Gallelli L.; Badolato M.; Carullo G.; Cione E.; Targeting neuropathic pain: Pathobiology, current treatment and peptidomimetics as a new therapeutic opportunity. Curr Med Chem 2020,27(9),1469-1500","journal-title":"Curr Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","volume":"338","author":"Kremer M.","year":"2016","unstructured":"Kremer M.; Salvat E.; Muller A.; Yalcin I.; Barrot M.; Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 2016,338,183-206","journal-title":"Neuroscience"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40122-017-0091-4","volume":"6","author":"Fornasari D.","year":"2017","unstructured":"Fornasari D.; Pharmacotherapy for neuropathic pain: A review. Pain Ther 2017,6(S1)(Suppl. 1),25-33","journal-title":"Pain Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jphp.13241","volume":"72","author":"Khdour M.R.","year":"2020","unstructured":"Khdour M.R.; Treatment of diabetic peripheral neuropathy: A review. J Pharm Pharmacol 2020,72(7),863-872","journal-title":"J Pharm Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.tips.2013.04.001","volume":"34","author":"Stahl S.M.","year":"2013","unstructured":"Stahl S.M.; Porreca F.; Taylor C.P.; Cheung R.; Thorpe A.J.; Clair A.; The diverse therapeutic actions of pregabalin: Is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci 2013,34(6),332-339","journal-title":"Trends Pharmacol Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40265-017-0747-8","volume":"77","author":"Widerstr\u00f6m-Noga E.","year":"2017","unstructured":"Widerstr\u00f6m-Noga E.; Neuropathic pain and spinal cord injury: Phenotypes and pharmacological management. Drugs 2017,77(9),967-984","journal-title":"Drugs"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pmr.2015.01.005","volume":"26","author":"Tauben D.","year":"2015","unstructured":"Tauben D.; Nonopioid medications for pain. Phys Med Rehabil Clin N Am 2015,26(2),219-248","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40265-020-01259-2","volume":"80","author":"Alam U.","year":"2020","unstructured":"Alam U.; Sloan G.; Tesfaye S.; Treating pain in diabetic neuropathy: Current and developmental drugs. Drugs 2020,80(4),363-384","journal-title":"Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.wneu.2015.04.025","volume":"84","author":"Chivukula S.","year":"2015","unstructured":"Chivukula S.; Tempel Z.J.; Chen C.J.; Shin S.S.; Gande A.V.; Moossy J.J.; Spinal and nucleus caudalis dorsal root entry zone lesioning for chronic pain: Efficacy and outcomes. World Neurosurg 2015,84(2),494-504","journal-title":"World Neurosurg"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/ar1971","volume":"8","author":"Arnold L.M.","year":"2006","unstructured":"Arnold L.M.; Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006,8(4),212","journal-title":"Arthritis Res Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11062-013-9338-9","volume":"45","author":"Stemkowski P.L.","year":"2013","unstructured":"Stemkowski P.L.; Biggs J.E.; Chen Y.; Bukhanova N.; Kumar N.; Smith P.A.; Understanding and treating neuropathic pain. Neurophysiology 2013,45(1),67-78","journal-title":"Neurophysiology"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"e1468","DOI":"10.1002\/wcms.1468","volume":"10","author":"Schaller D.","year":"2020","unstructured":"Schaller D.; Sribar D.; Noonan T.; Deng L.; Nguyen T.N.; Pach S.; Machalz D.; Bermudez M.; Wolber G.; Next generation 3D pharmacophore modeling. WIREs Comput. Mol Sci 2020,10(4),e1468","journal-title":"Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","volume":"14","author":"Chincholkar M.","year":"2020","unstructured":"Chincholkar M.; Gabapentinoids: Pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain 2020,14(2),104-114","journal-title":"Br J Pain"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5606\/tftrd.2017.651","volume":"63","author":"\u0130lhanl\u0131 \u0130.","year":"2017","unstructured":"\u0130lhanl\u0131 \u0130.; G\u00fcder N.; G\u00fcl M.; Gabapentinoids in penitentiaries: An abuse and addiction research. Turk J Phys Med Rehabil 2017,63(4),318-328","journal-title":"Turk J Phys Med Rehabil"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jphs.2021.01.002","volume":"146","author":"Oyama M.","year":"2021","unstructured":"Oyama M.; Watanabe S.; Iwai T.; Tanabe M.; Mirogabalin activates the descending noradrenergic system by binding to the \u03b1\u03b4-1 subunit of voltage-gated Ca channels to generate analgesic effects. J Pharmacol Sci 2021,146(1),33-39","journal-title":"J Pharmacol Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","volume":"142","author":"Taylor C.P.","year":"2009","unstructured":"Taylor C.P.; Mechanisms of analgesia by gabapentin and pregabalin--calcium channel \u03b12-\u03b4 [Cavalpha2-\u03b4] ligands. Pain 2009,142(1-2),13-16","journal-title":"Pain"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.bja.2018.02.066","volume":"120","author":"Chincholkar M.","year":"2018","unstructured":"Chincholkar M.; Analgesic mechanisms of gabapentinoids and effects in experimental pain models: A narrative review. Br J Anaesth 2018,120(6),1315-1334","journal-title":"Br J Anaesth"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.brainresbull.2019.12.001","volume":"155","author":"B\u00e1n E.G.","year":"2020","unstructured":"B\u00e1n E.G.; Brassai A.; Vizi E.S.; The role of the endogenous neurotransmitters associated with neuropathic pain and in the opioid crisis: The innate pain-relieving system. Brain Res Bull 2020,155,129-136","journal-title":"Brain Res Bull"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","volume":"36","author":"Kukkar A.","year":"2013","unstructured":"Kukkar A.; Bali A.; Singh N.; Jaggi A.S.; Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 2013,36(3),237-251","journal-title":"Arch Pharm Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","volume":"6","author":"Sills G.J.","year":"2006","unstructured":"Sills G.J.; The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006,6(1),108-113","journal-title":"Curr Opin Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.bmcl.2009.10.089","volume":"20","author":"Blakemore D.C.","year":"2010","unstructured":"Blakemore D.C.; Bryans J.S.; Carnell P.; Chessum N.E.; Field M.J.; Kinsella N.; Kinsora J.K.; Osborne S.A.; Williams S.C.; Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett 2010,20(1),362-365","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","first-page":"249","volume":"7","author":"Beal B.","year":"2012","unstructured":"Beal B.; Moeller-Bertram T.; Schilling J.M.; Wallace M.S.; Gabapentin for once-daily treatment of post-herpetic neuralgia: A review. Clin Interv Aging 2012,7,249-255","journal-title":"Clin Interv Aging"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"Calandre E.P.","year":"2016","unstructured":"Calandre E.P.; Rico-Villademoros F.; Slim M.; Alphadelta ligands, gabapentin, pregabalin and mirogabalin: A review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 2016,16(11),1263-1277","journal-title":"Expert Rev Neurother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/09546634.2016.1163315","volume":"28","author":"Wang J.","year":"2017","unstructured":"Wang J.; Zhu Y.; Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. J Dermatolog Treat 2017,28(1),65-77","journal-title":"J Dermatolog Treat"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.104.067959","volume":"311","author":"Cundy K.C.","year":"2004","unstructured":"Cundy K.C.; Annamalai T.; Bu L.; De Vera J.; Estrela J.; Luo W.; Shirsat P.; Torneros A.; Yao F.; Zou J.; Barrett R.W.; Gallop M.A.; XP13512 [(+\/-)-1-([(\u03b1-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004,311(1),324-333","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/jpet.104.067934","volume":"311","author":"Cundy K.C.","year":"2004","unstructured":"Cundy K.C.; Branch R.; Chernov-Rogan T.; Dias T.; Estrada T.; Hold K.; Koller K.; Liu X.; Mann A.; Panuwat M.; Raillard S.P.; Upadhyay S.; Wu Q.Q.; Xiang J.N.; Yan H.; Zerangue N.; Zhou C.X.; Barrett R.W.; Gallop M.A.; XP13512 [(+\/-)-1-([(\u03b1-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004,311(1),315-323","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0091270008322909","volume":"48","author":"Cundy K.C.","year":"2008","unstructured":"Cundy K.C.; Sastry S.; Luo W.; Zou J.; Moors T.L.; Canafax D.M.; Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008,48(12),1378-1388","journal-title":"J Clin Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.clinthera.2011.12.004","volume":"34","author":"Lal R.","year":"2012","unstructured":"Lal R.; Sukbuntherng J.; Luo W.; Chen D.; Blumenthal R.; Ho J.; Cundy K.C.; Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther 2012,34(1),201-213","journal-title":"Clin Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"Schifano F.","year":"2014","unstructured":"Schifano F.; Misuse and abuse of pregabalin and gabapentin: Cause for concern? CNS Drugs 2014,28(6),491-496","journal-title":"CNS Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"Dworkin R.H.","year":"2010","unstructured":"Dworkin R.H.; O\u2019Connor A.B.; Audette J.; Baron R.; Gourlay G.K.; Haanp\u00e4 M.L.; Kent J.L.; Krane E.J.; Lebel A.A.; Levy R.M.; Mackey S.C.; Mayer J.; Miaskowski C.; Raja S.N.; Rice A.S.; Schmader K.E.; Stacey B.; Stanos S.; Treede R.D.; Turk D.C.; Walco G.A.; Wells C.D.; Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010,85(3)(Suppl.),S3-S14","journal-title":"Mayo Clin Proc"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/ph14020112","volume":"14","author":"Zaj\u0105czkowska R.","year":"2021","unstructured":"Zaj\u0105czkowska R.; Mika J.; Leppert W.; Kocot-K\u0119pska M.; Malec-Milewska M.; Wordliczek J.; Mirogabalin-a novel selective ligand for the alpha2delta calcium channel subunit. Pharmaceuticals (Basel) 2021,14(2),112","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Domon Y.","year":"2018","unstructured":"Domon Y.; Arakawa N.; Inoue T.; Matsuda F.; Takahashi M.; Yamamura N.; Kai K.; Kitano Y.; Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 2018,365(3),573-582","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdi.13178","volume":"11","author":"Baba M.","year":"2020","unstructured":"Baba M.; Matsui N.; Kuroha M.; Wasaki Y.; Ohwada S.; Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig 2020,11(3),693-698","journal-title":"J Diabetes Investig"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.clinthera.2021.03.015","volume":"43","author":"Kato J.","year":"2021","unstructured":"Kato J.; Baba M.; Kuroha M.; Kakehi Y.; Murayama E.; Wasaki Y.; Ohwada S.; Safety and efficacy of mirogabalin for peripheral neuropathic pain: Pooled analysis of two pivotal phase III studies. Clin Ther 2021,43(5),822-835.e16","journal-title":"Clin Ther"},{"key":"ref=61","first-page":"659","volume":"73","author":"Domon Y.","year":"2018","unstructured":"Domon Y.; Kitano Y.; Makino M.; Analgesic effects of the novel \u03b1 \u03b4 ligand mirogabalin in a rat model of spinal cord injury. Pharmazie 2018,73(11),659-661","journal-title":"Pharmazie"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jcph.567","volume":"56","author":"Hutmacher M.M.","year":"2016","unstructured":"Hutmacher M.M.; Frame B.; Miller R.; Truitt K.; Merante D.; Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol 2016,56(1),67-77","journal-title":"J Clin Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40261-018-0692-7","volume":"38","author":"Duchin K.","year":"2018","unstructured":"Duchin K.; Senaldi G.; Warren V.; Marbury T.; Lasseter K.; Zahir H.; Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin. Clin Drug Investig 2018,38(11),1001-1009","journal-title":"Clin Drug Investig"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/JPR.S255345","volume":"13","author":"Baba M.","year":"2020","unstructured":"Baba M.; Takatsuna H.; Matsui N.; Ohwada S.; Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or post-herpetic neuralgia: A phase III, open-label, 14-week study. J Pain Res 2020,13,1811-1821","journal-title":"J Pain Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1124\/jpet.120.000315","volume":"376","author":"Gou X.","year":"2021","unstructured":"Gou X.; Yu X.; Bai D.; Tan B.; Cao P.; Qian M.; Zheng X.; Chen L.; Shi Z.; Li Y.; Ye F.; Liang Y.; Ni J.; Pharmacology and mechanism of action of HSK16149, a selective ligand of \u03b12\u03b4 subunit of voltage-gated calcium channel with analgesic activity in animal models of chronic pain. J Pharmacol Exp Ther 2021,376(3),330-337","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=66","author":"Maghani P.","year":"2015","unstructured":"Maghani P.; Kricek F.; Gamma-aminobutyric acid (GABA) analogues for the treatment of pain and other diseases. 2015"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1016\/j.bmcl.2006.03.083","volume":"16","author":"Schwarz J.B.","year":"2006","unstructured":"Schwarz J.B.; Colbry N.L.; Zhu Z.; Nichelson B.; Barta N.S.; Lin K.; Hudack R.A.; Gibbons S.E.; Galatsis P.; DeOrazio R.J.; Manning D.D.; Vartanian M.G.; Kinsora J.J.; Lotarski S.M.; Li Z.; Dickerson M.R.; El-Kattan A.; Thorpe A.J.; Donevan S.D.; Taylor C.P.; Wustrow D.J.; Carboxylate bioisosteres of pregabalin. Bioorg Med Chem Lett 2006,16(13),3559-3563","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.juro.2012.05.010","volume":"188","author":"Nickel J.C.","year":"2012","unstructured":"Nickel J.C.; Crossland A.; Davis E.; Haab F.; Mills I.W.; Rovner E.; Scholfield D.; Crook T.; Investigation of a Ca channel \u03b12\u03b4 ligand for the treatment of interstitial cystitis: Results of a randomized, double-blind, placebo controlled phase II trial. J Urol 2012,188(3),817-823","journal-title":"J Urol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1517\/13543784.2016.1162290","volume":"25","author":"Chuang Y.C.","year":"2016","unstructured":"Chuang Y.C.; Chermansky C.; Kashyap M.; Tyagi P.; Investigational drugs for bladder pain syndrome (BPS) \/ interstitial cystitis (IC). Expert Opin Investig Drugs 2016,25(5),521-529","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bmcl.2009.11.118","volume":"20","author":"Blakemore D.C.","year":"2010","unstructured":"Blakemore D.C.; Bryans J.S.; Carnell P.; Carr C.L.; Chessum N.E.; Field M.J.; Kinsella N.; Osborne S.A.; Warren A.N.; Williams S.C.; Synthesis and in vivo evaluation of bicyclic gababutins. Bioorg Med Chem Lett 2010,20(2),461-464","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bmcl.2009.10.121","volume":"20","author":"Blakemore D.C.","year":"2010","unstructured":"Blakemore D.C.; Bryans J.S.; Carnell P.; Field M.J.; Kinsella N.; Kinsora J.K.; Meltzer L.T.; Osborne S.A.; Thompson L.R.; Williams S.C.; Synthesis and in vivo evaluation of 3,4-disubstituted gababutins. Bioorg Med Chem Lett 2010,20(1),248-251","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2125.2009.03444.x","volume":"68","author":"Corrigan B.","year":"2009","unstructured":"Corrigan B.; Feltner D.E.; Ouellet D.; Werth J.L.; Moton A.E.; Gibson G.; Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit. Br J Clin Pharmacol 2009,68(2),174-180","journal-title":"Br J Clin Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1007\/s11095-011-0490-x","volume":"28","author":"Kjellsson M.C.","year":"2011","unstructured":"Kjellsson M.C.; Ouellet D.; Corrigan B.; Karlsson M.O.; Modeling sleep data for a new drug in development using markov mixed-effects models. Pharm Res 2011,28(10),2610-2627","journal-title":"Pharm Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000110737","volume":"81","author":"Ohashi K.","year":"2008","unstructured":"Ohashi K.; Kawai M.; Ninomiya N.; Taylor C.; Kurebayashi Y.; Effect of a new \u03b1 2 \u03b4 ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats. Pharmacology 2008,81(2),144-150","journal-title":"Pharmacology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bmcl.2008.10.101","volume":"19","author":"Wustrow D.J.","year":"2009","unstructured":"Wustrow D.J.; Belliotti T.R.; Capiris T.; Kneen C.O.; Bryans J.S.; Field M.J.; Williams D.; El-Kattan A.; Buchholz L.; Kinsora J.J.; Lotarski S.M.; Vartanian M.G.; Taylor C.P.; Donevan S.D.; Thorpe A.J.; Schwarz J.B.; Oxadiazolone bioisosteres of pregabalin and gabapentin. Bioorg Med Chem Lett 2009,19(1),247-250","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/ard.2005.041855","volume":"65","author":"Boileau C.","year":"2006","unstructured":"Boileau C.; Martel-Pelletier J.; Brunet J.; Schrier D.; Flory C.; Boily M.; Pelletier J.P.; PD-0200347, an \u03b12\u03b4 ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1\/2 pathway in osteoarthritic chondrocytes: A PKCalpha dependent effect. Ann Rheum Dis 2006,65(5),573-580","journal-title":"Ann Rheum Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.20809","volume":"52","author":"Boileau C.","year":"2005","unstructured":"Boileau C.; Martel-Pelletier J.; Brunet J.; Tardif G.; Schrier D.; Flory C.; El-Kattan A.; Boily M.; Pelletier J.P.; Oral treatment with PD-0200347, an \u03b12\u03b4 ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum 2005,52(2),488-500","journal-title":"Arthritis Rheum"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","volume":"67","author":"Dixon S.L.","year":"2006","unstructured":"Dixon S.L.; Smondyrev A.M.; Rao S.N.; PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 2006,67(5),370-372","journal-title":"Chem Biol Drug Des"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220407093727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203226\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220407093727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T20:52:21Z","timestamp":1700427141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203226\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":78,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220407093727","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}